Botulism - Pipeline Review, H2 2017 - Product Image

Botulism - Pipeline Review, H2 2017

  • ID: 4334019
  • Report
  • 45 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • CytoDel LLC
  • Hawaii Biotech Inc
  • Medy-Tox Inc
  • Microbiotix Inc
  • Nanotherapeutics Inc
  • XOMA Corp
  • MORE
Botulism - Pipeline Review, H2 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Botulism - Pipeline Review, H2 2017, provides an overview of the Botulism (Infectious Disease) pipeline landscape.

Botulism is a rare but serious illness. The cause is a toxin (poison) made by a bacterium called Clostridium botulinum. It occurs naturally in soil. Food borne botulism comes from eating foods contaminated with the toxin. Symptoms include double or blurred vision, drooping eyelids, slurred speech, difficulty swallowing, dry mouth, and muscle weakness. Treatment may include antitoxins, intensive medical care, or surgery of infected wounds.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Botulism - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Botulism (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Botulism (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Botulism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 3, 6 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Botulism (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Botulism (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Botulism (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Botulism (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Botulism (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Botulism (Infectious Disease)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Botulism (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Botulism (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • CytoDel LLC
  • Hawaii Biotech Inc
  • Medy-Tox Inc
  • Microbiotix Inc
  • Nanotherapeutics Inc
  • XOMA Corp
  • MORE
Introduction

Botulism - Overview

Botulism - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Botulism - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Botulism - Companies Involved in Therapeutics Development

CytoDel LLC

Hawaii Biotech Inc

Medy-Tox Inc

Microbiotix Inc

Nanotherapeutics Inc

XOMA Corp

Botulism - Drug Profiles

BoNT/A HcR4 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

botulism [serotype C] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

botulism [serotypes A, B, C, D, E] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

botulism [serotypes A, B, E] (trivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Ctyo-111 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit Botulinum Neurotoxin Type A for Botulism - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit Botulinum Toxin for Botulism - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NTM-1634 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OSX-400 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OSX-400 Backups - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Polyclonal Antibody to Inhibit Botulinum Toxin for Botulism - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Peptides to Inhibit Botulinum Toxin for Botulism - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Botulism - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit BoNT/A LC for Botulism - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Botulinum Neurotoxin Type A for Botulism - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XOMA-3AB - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XOMA-3BB - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Botulism - Dormant Projects

Botulism - Discontinued Products

Botulism - Product Development Milestones

Featured News & Press Releases

May 03, 2011: XOMA 3AB, New Triple-Antibody Anti-Botulinum Neurotoxin Product, Enters Phase I Clinical Testing

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Botulism, H2

Number of Products under Development by Companies, H2

Number of Products under Development by Universities/Institutes, H2

Products under Development by Companies, H2

Products under Development by Universities/Institutes, H2

Number of Products by Stage and Target, H2

Number of Products by Stage and Mechanism of Action, H2

Number of Products by Stage and Route of Administration, H2

Number of Products by Stage and Molecule Type, H2

Botulism - Pipeline by CytoDel LLC, H2

Botulism - Pipeline by Hawaii Biotech Inc, H2

Botulism - Pipeline by Medy-Tox Inc, H2

Botulism - Pipeline by Microbiotix Inc, H2

Botulism - Pipeline by Nanotherapeutics Inc, H2

Botulism - Pipeline by XOMA Corp, H2

Botulism - Dormant Projects, H2

Botulism - Discontinued Products, H2

List of Figures

Number of Products under Development for Botulism, H2

Number of Products under Development by Companies, H2

Number of Products under Development by Universities/Institutes, H2

Number of Products by Targets, H2

Number of Products by Stage and Targets, H2

Number of Products by Mechanism of Actions, H2

Number of Products by Stage and Mechanism of Actions, H2

Number of Products by Routes of Administration, H2

Number of Products by Stage and Routes of Administration, H2

Number of Products by Molecule Types, H2

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • CytoDel LLC
  • Hawaii Biotech Inc
  • Medy-Tox Inc
  • Microbiotix Inc
  • Nanotherapeutics Inc
  • XOMA Corp
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll